Sporotrichosis in the Highlands of Madagascar, 2013–20171

Rasamoelina, Tahinamandranto; Maubon, Danièle; Raharolahy, Onivola; Razanakoto, Harinjara; Rakotozandrindrainy, Njary; Rakotomalala, Fetra Angelot; Bailly, Sébastien; Sendrasoa, Fandresena Arilala; Ranaivo, Irina Mamisoa; Andrianarison, Malalaniaina; Rakotonirina, Benja; Andriantsimahavandy, A.; Rabenja, F. Rapelanoro; Andrianarivelo, Mala Rakoto; Ramarozatovo, Lala Soavina; Cornet, Muriel

doi:10.3201/eid2510.190700

Cited by 17 publications

(29 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, these studies did not specify any previous treatments received by patients before inclusion. In addition, it has been reported that the clinical presentation of CBM does not appear to differ according to fungal species (Bonifaz et al, 2001), an observation that we confirmed in our entire cohort of 50 patients recruited from 2013 to 2018 (Rasamoelina et al, 2019). Our study showed that previous treatment may change the appearance of the lesions, which appeared smoother and shinier, less warty, less squamous, pink, and completely depigmented.…”

Section: Discussionsupporting

confidence: 85%

See 1 more Smart Citation

Clinical aspects of previously treated chromoblastomycosis: A case series from Madagascar

Sendrasoa

Razanakoto

Rakotoarisaona

et al. 2020

International Journal of Infectious Diseases

Self Cite

View full text Add to dashboard Cite

To describe the clinical aspects of chromoblastomycosis (CBM) presented by patients who had received incomplete antifungal treatment before consultation. Methods: A prospective study of patients with clinically suspected CBM was performed between 2013 and 2018 in the Department of Dermatology at the University Hospital Antananarivo, and during consultation campaigns. Results: Patients develop CBM over a period of more than 10 years, and many will have already received antifungals prescribed by general practitioners before consulting with a dermatologist. Such treatment obviously modifies the clinical presentation. From the 63 CBM patients in this large study, we describe 12 patients who received oral antifungals (terbinafine, griseofulvine, itraconazole, fluconazole) before consultation. The most frequent clinical aspect presented by these patients was cicatricial lesions, which are characteristically smooth and non-elevated, and enlarge by peripheral extension, with atrophic scarring at the center. Conclusion:Our study is the first to show that cicatricial lesions are a clinical aspect presented by CBM patients who received antifungals before presentation.

show abstract

Section: Discussionsupporting

confidence: 85%

“…A prospective descriptive study of patients with clinically suspected CBM or another chronic dermatomycosis was performed (Rasamoelina et al, 2019) (De Pauw et al, 2008).…”

Section: Methodsmentioning

confidence: 99%

Clinical aspects of previously treated chromoblastomycosis: A case series from Madagascar

Sendrasoa

Razanakoto

Rakotoarisaona

et al. 2020

International Journal of Infectious Diseases

Self Cite

View full text Add to dashboard Cite

show abstract

“…3) [109]. Outside the main transmission area in South Africa, sporadic cases have been reported in Madagascar [116], Zimbabwe [117], Nigeria [118] and Sudan [119]. Surprisingly, the HIV/AIDS epidemic in South Africa does not appear to be associated with a concomitant increase in sporotrichosis cases, which remain infrequent [120,121].…”

Section: The Geography Of Sporothrix and Sporotrichosismentioning

confidence: 99%

The threat of emerging and re-emerging pathogenic Sporothrix species

et al. 2020

View full text Add to dashboard Cite

Sporotrichosis is a neglected subcutaneous mycosis of humans and animals acquired by traumatic inoculation of soil and plant material (classical route) contaminated with infectious propagules of the pathogen or being bitten/scratched by infected cats (alternative route). Within a genus composed of 53 species displaying an essentially environmental core, there are only a few members which have considerable impacts on human or animal health. Infections are typically caused by S. brasiliensis, S. schenckii or S. globosa. Rare mammal pathogens include members of the S. pallida and S. stenocereus complexes. To illustrate the tremendous impact of emerging zoonotic sporotrichosis on public health, we discuss the main features of the expanding epidemics driven by S. brasiliensis in cats and humans. The cat entry in the transmission chain of sporotrichosis, causing epizooties (cat-cat) or zoonosis (cat-human), has contributed to the definition of new paradigms in Sporothrix transmission, reaching epidemic levels, making the disease a serious public health problem. Indeed, S. brasiliensis infection in humans and animals is likely to become even more important in the future, with projections of its expansion in biogeographic domains and host range, as well as greater virulence in mammals. Therefore, lessons from a long-standing outbreak in the state of Rio de Janeiro about the source and distribution of the etiological agents among outbreak areas can be used to create better control and prevention plans and increase awareness of sporotrichosis as a serious emerging zoonotic disease. Keywords Sporothrix Á Sporotrichosis Á Emerging zoonoses Á Control and prevention Á Preparedness and biodefense Á Pathogenicity Á Virulence Á Sporothrix brasiliensis Á Neglected tropical diseases The story behind the Sporothrix species pathogenic to mammals Sporotrichosis is a fungal disease caused by the infection of Sporothrix spp. It usually affects the skin Handling editor: Ferry Hagen.

show abstract

“…

…”

mentioning

confidence: 99%

“…Since 2013, we have established a cross-sectional study to document the current epidemiology of implantation mycoses in Madagascar, including chromoblastomycosis (12). Clinical diagnosis and fungal identification were confirmed by using molecular biology methods.…”

mentioning

confidence: 99%

Endemic Chromoblastomycosis Caused Predominantly by Fonsecaea nubica, Madagascar1

Rasamoelina¹,

Maubon²,

Andrianarison³

et al. 2020

Emerg. Infect. Dis.

Self Cite

View full text Add to dashboard Cite

We conducted a cross-sectional study as described (12). We recruited patients with clinically suspected chromoblastomycosis or another chronic dermatomycosis during March 2013-June 2017 at the Dermatology Department of the Joseph Raseta Befelatanana University Hospital in Antananarivo or during advanced consultation campaigns in districts (Figure 1, panel A). A clinical and demographic information form was completed for each participant. This study was approved by the Ethics Committee for Biomedical Research of the Ministry of Public Health of Madagascar (authorization no. 66-MSANP/CE). Case DefinitionWe provide clinical, mycological, histological, severity and prognostic criteria used for classifying cases in this study (Table 1). Cases were identified after a monthly consultation between the clinicians of the

show abstract

Sporotrichosis in the Highlands of Madagascar, 2013–20171

Cited by 17 publications

References 23 publications

Clinical aspects of previously treated chromoblastomycosis: A case series from Madagascar

Clinical aspects of previously treated chromoblastomycosis: A case series from Madagascar

The threat of emerging and re-emerging pathogenic Sporothrix species

Endemic Chromoblastomycosis Caused Predominantly by Fonsecaea nubica, Madagascar1

Contact Info

Product

Resources

About